Jessy Delaye

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette et al. · The Lancet Oncology · 2018 · 316 citations

Medicine, Oncology, Pharmacology +13

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Nathalie Gaspar, Bob‐Valéry Occéan, Hélène Pacquement et al. · European Journal of Cancer · 2017 · 145 citations

Medicine, Oncology, Pharmacology +10

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

Jérôme Fayette, Caroline Even, Laurence Digue et al. · Journal of Clinical Oncology · 2019 · 58 citations

Medicine, Oncology, Otolaryngology +13

Prevalence and characteristics of HPV-driven oropharyngeal cancer in France

H. Mirghani, Carine Bellera, Jessy Delaye et al. · Cancer Epidemiology · 2019 · 43 citations

Medicine, Oncology, Cancer Prevention +6

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma

Caroline Brard, Sophie Piperno‐Neumann, Jessy Delaye et al. · BMJ Open · 2019 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17